Humanin Research Overview (also known as HN, Mitochondria-Derived Peptide, MDP, MTRNR2, HNG (Gly14-Humanin analog))
Humanin is a mitochondria-derived peptide encoded within the mitochondrial 16S ribosomal RNA region and associated with cytoprotective signaling. First described in 2001 in a study of Alzheimer's disease-resistant brain tissue, humanin has been investigated for effects on neuronal survival, mitochondrial function, inflammation, insulin sensitivity, cardiovascular injury, and aging. Its abundance generally declines with age in experimental and observational studies, although it is not an established clinical biomarker or approved therapy. Most evidence remains preclinical, and no standardized human dose or long-term safety profile has been established.
What Is Humanin?
Humanin is a small mitochondria-derived peptide (MDP) identified by Hashimoto and colleagues in 2001 during a search for protective factors in brain tissue resistant to familial Alzheimer's disease-associated toxicity. The original work showed that a peptide encoded by a short open reading frame within the mitochondrial genome could protect cultured neurons from cell death induced by several Alzheimer's disease-related insults, including amyloid-beta-associated toxicity. Humanin was therefore notable not only for its biological activity but also for its unusual genetic origin. Unlike most signaling peptides, which are encoded in nuclear DNA and translated on cytosolic ribosomes, humanin is encoded within the mitochondrial 16S ribosomal RNA, or MT-RNR2, region of mitochondrial DNA. The human MT-RNR2-associated open reading frame is commonly described as producing a 24-amino-acid humanin peptide, while sequence and length conventions can differ among species, constructs, and experimental preparations.
Humanin is classified with other mitochondria-derived peptides, including MOTS-c and small humanin-like peptides, as a retrograde signaling molecule that communicates mitochondrial state to the rest of the cell and to distant tissues. It has been detected or studied in the brain, liver, skeletal muscle, heart, testes, pancreas, kidney, and circulating blood, although tissue abundance, secretion, and measurement methods vary substantially. Humanin expression and circulating concentrations tend to decline with advancing age in animal models and in several human observational studies. Lower levels have also been associated in some studies with metabolic disease, cardiovascular risk, frailty, or neurodegenerative conditions. These associations do not establish that reduced humanin causes aging or disease. Rather, they support investigation of humanin as a possible component of mitochondrial stress signaling and as a candidate biomarker or therapeutic lead.
Research Indications
Neuroprotection & Cellular Stress
Amyloid-beta toxicity models
Humanin was initially identified by its ability to reduce neuronal cell death in cellular models expressing familial Alzheimer disease genes or exposed to amyloid-beta. This remains primarily preclinical evidence.
Apoptotic stress signaling
Experimental work indicates that Humanin can modulate pro-apoptotic signaling, including pathways involving BAX and related mitochondrial stress responses.
Metabolic & Endocrine Signaling
Insulin action in animal studies
In rodent studies, centrally and peripherally administered Humanin analogs have been reported to influence insulin sensitivity and glucose handling.
Growth hormone and IGF-axis associations
Circulating Humanin concentrations have been associated with age and growth hormone/IGF-related biology in observational and experimental research; causal clinical effects remain unestablished.
Cardiovascular & Tissue Protection
Ischemia-reperfusion models
Humanin and potent analogs have shown cytoprotective effects in experimental cardiac and vascular injury models. Translation to clinical cardiovascular outcomes is unknown.
Endothelial stress research
Preclinical findings suggest effects on oxidative stress, endothelial cell survival, and inflammatory signaling under experimental conditions.
Longevity Biology & Mitochondrial-Derived Peptides
Age-related biomarker research
Humanin is studied as a mitochondrial-derived peptide whose circulating levels may change with age and metabolic state. It is not an established longevity treatment or biomarker.
Mitochondrial-to-nuclear communication
Research explores Humanin as part of mitochondrial retrograde signaling that may coordinate cellular responses to stress, nutrient availability, and damage.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Conservative exploratory research | 0.1–0.2 mg | 2–3 times weekly | Subcutaneous |
| Intermittent peptide protocol | 0.2–0.5 mg | Every other day | Subcutaneous |
| Short research cycle | 0.5 mg | Daily for limited duration | Subcutaneous |
| Clinical-study analog context | Protocol-specific | Protocol-specific | Parenteral |
Timing
No clinically validated Humanin dosing schedule exists. Research protocols commonly use intermittent administration and predefined short cycles; timing relative to meals or exercise has not been established in human clinical studies.
Peptide Interactions
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
Both are mitochondrial-derived peptides studied in stress and metabolic signaling. Combined use lacks controlled human safety or efficacy data.
Both may influence metabolic signaling and glucose handling. Monitor for changes in glycemic control; no direct clinical interaction study is available.
Animal data suggest possible effects on insulin action. People using glucose-lowering therapy should not combine without clinician oversight.
Humanin biology is linked experimentally with the GH/IGF axis. The implications of concomitant therapy are uncertain and warrant medical review.
Because Humanin has cytoprotective and anti-apoptotic activity in experimental systems, unsupervised use during chemotherapy or cancer treatment may be inappropriate.
No direct interaction is established. Their proposed mechanisms differ, but combination safety data for injectable use are absent.
Reported Research Timeline
01First 24 hours (reported in cited studies): no reliable subjective effect should be expected. Observe only for injection-site reactions or unexpected acute symptoms.
02Days 2–7 (reported in cited studies): informal reports may include no noticeable change; Humanin does not have established acute human effects at research-use doses.
03Weeks 2–4 (reported in cited studies): any perceived changes in energy, recovery, or metabolic markers remain anecdotal and cannot be attributed confidently without controlled measurement.
04Weeks 4–8 (reported in cited studies): research-oriented monitoring may focus on tolerability and clinically relevant laboratory markers under professional supervision, particularly if glucose regulation is a concern.
05Months 2–3 (reported in cited studies): there are no validated clinical outcome targets or evidence-based criteria for continuing Humanin outside a formal research setting.
06Long term (reported in cited studies): long-term safety, immunogenicity, and clinical benefit in humans are unknown; do not interpret absence of immediate symptoms as evidence of safety.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Humanin is an investigational peptide; it is not an approved treatment for aging, neurodegeneration, metabolic disease, or cardiovascular disease.
Human safety, pharmacokinetic, and long-term immunogenicity data for nonclinical injectable preparations are limited.
Avoid use during pregnancy or breastfeeding because reproductive and developmental safety data are insufficient.
Use particular caution with diabetes, hypoglycemia history, insulin, or other glucose-lowering medications due to experimental effects on insulin signaling.
Avoid unsupervised use with active malignancy or during chemotherapy, radiotherapy, or other cancer-directed treatment.
Injection-related risk includes contamination, dosing error, local tissue injury, and allergic reaction; sterile technique and appropriate storage are essential.
Seek Medical Attention If:
You develop facial or throat swelling, wheezing, widespread hives, fainting, or other signs of a severe allergic reaction.
An injection site becomes increasingly painful, warm, swollen, draining, or associated with fever or chills.
You experience confusion, loss of consciousness, seizure, severe weakness, or symptoms suggestive of severe hypoglycemia.
You develop chest pain, severe shortness of breath, persistent palpitations, or new neurologic symptoms.
Quality Indicators
Verified Marker
Peptide identity and purity documentation
Request a lot-specific certificate of analysis identifying Humanin sequence, stated peptide content, analytical method, and batch number.
Verified Marker
HPLC and mass-spectrometry testing
Prefer independent HPLC purity testing paired with mass spectrometry confirmation rather than an unlabeled or generic purity claim.
Verified Marker
Clear reconstituted solution
After reconstitution according to validated instructions, solution should be clear and free of visible particles, unexpected discoloration, or persistent cloudiness.
Acceptable Range
Lyophilized cake appearance and cold chain
A uniform white to off-white lyophilized cake and documented refrigerated storage are generally expected, though appearance alone cannot confirm sterility or potency.
Quality Concern
Missing sterility, endotoxin, or vial traceability data
Do not rely on products lacking lot-specific labeling, sterility and endotoxin documentation, storage history, or a traceable source for an injectable preparation.
Research Citations
- A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ
Hashimoto, Y., Niikura, T., Tajima, H., et al., 2001, Proceedings of the National Academy of Sciences of the USA - Humanin: a novel central regulator of peripheral insulin action
Muzumdar, R. H., Huffman, D. M., Atzmon, G., et al., 2009, PLoS One - The emerging role of the mitochondrial-derived peptide humanin in stress resistance
Yen, K., Lee, C., Mehta, H., et al., 2013, Journal of Molecular Endocrinology - Mitochondrial-derived peptides: new players in aging and age-related diseases?
Cobb, L. J., Lee, C., Xiao, J., et al., 2016, Trends in Biochemical Sciences - Humanin protects against chemotherapy-induced side effects
Sponne, I., Fifre, A., Drouet, B., et al., 2008, Proceedings of the National Academy of Sciences of the USA
Research Focus
mitochondria-derived peptide, cytoprotection, longevity, anti-aging, Alzheimer's protection, insulin sensitivity, neuroprotection, IGF-1 signaling
Frequently Asked Questions
What should researchers watch for with Humanin?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Humanin?
First 24 hours (reported in cited studies): no reliable subjective effect should be expected. Observe only for injection-site reactions or unexpected acute symptoms.
How is Humanin typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →